Published in TB and Outbreaks Week, March 26th, 2002
For the fourth quarter of 2001, total revenues were $1.6 million compared with $1.7 million in the fourth quarter of 2000. Total operating expenses were $12.4 million for the fourth quarter of 2001 compared with $8.1 million for the fourth quarter of 2000. The increase in operating expenses resulted principally from expanded clinical trials. For the fourth quarter of 2001, Versicor reported a net loss of $10.5 million, or a loss per share of $0.45 on 23.2 million weighted average shares outstanding. This compares to a net loss of $5.1 million in the fourth quarter of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.